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Neonatal immune responses are generally char-
acterized by low antibody, poor cytotoxic, and 
Th2 cell–skewed T cell responses to intra-
cellular pathogens and vaccines (1). The mecha-
nisms underlying the weakness of immune 
responses in newborns remain poorly under-
stood. In neonates, the maturation of the   immune 
system is not totally achieved, which leads to 
quantitative and qualitative diff  erences in im-
mune cell subsets between neonates and adults (2). 
Defects in neonatal adaptive immunity have been 
thoroughly investigated, but little is known 
about neonatal innate immunity.   Neonatal T cells 
may develop adult-like responses under appro-
priate stimulation (2). The key issue is there-
fore the absence of such appropriate stimulatory 
conditions after infection or vaccination early 
in life.
Innate immune cells, including macrophages, 
DCs, and natural killer cells (3), operate upstream 
and are critical for early host defense and the 
  establishment of acquired immunity. The innate 
immune system recognizes microorganisms via a 
limited number of germline-encoded pattern-
recognition receptors, among which 11 Toll-
like receptors (TLRs) have been identifi  ed. The 
patterns of TLR expression on innate cells 
display diff  erential regulation, as shown by the 
  expression of TLR7 and TLR9 on plasmacytoid 
DCs (pDCs), whereas a wider range of TLRs 
are expressed by conventional DCs (cDCs) (4). 
The stimulation of cells with TLR ligands 
(TLR-Ls) activates myeloid diff  erentiation factor 
88 (MyD88)–dependent or –independent path-
ways, resulting in production of the cytokines 
and chemokines required to establish the infl  am-
matory environment necessary for   antimicrobial 
activity, the activation and recruitment of im-
mune eff  ector cells, and the subsequent devel-
opment of adaptive immune responses (5).
Cord blood IL-12 and TNF-α responses 
to microbial and TLR-L stimulation are much 
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Newborns and infants are highly susceptible to viral and bacterial infections, but the 
  underlying mechanism remains poorly understood. We show that neonatal B cells effectively 
control the production of proinfl  ammatory cytokines by both neonatal plasmacytoid and 
conventional dendritic cells, in an interleukin (IL) 10–dependent manner, after Toll-like 
receptor (TLR) 9 triggering. This antiinfl  ammatory property of neonatal B cells may extend 
to other TLR agonists (Pam3CSK4, lipopolysaccharide, and R848) and viruses. In the 
  absence of B cells or of CD5+ B cell subsets, neonatal mice developed stronger infl  ammatory 
responses and became lethally susceptible to CpG challenge after galactosamine sensitiza-
tion, whereas wild-type (WT) mice were resistant. Paradoxically, interferon (IFN)-𝗂/𝗃 
enhanced the infl  ammatory response to CpG challenge in adult mice, whereas they helped 
to control neonatal acute infl  ammation by stimulating the secretion of IL-10 by neonatal 
B cells. Finally, WT neonatal B cells rescued IL-10−/− neonates from a lethal CpG challenge, 
whereas IFN-𝗂/𝗃 receptor–defi  cient B cells did not. Our results show that type I IFNs 
support a negative regulatory role of neonatal B cells on TLR-mediated infl  ammation, with 
important implications for neonatal infl  ammation and infection.
CORRESPONDENCE
R. Lo-Man: 
rloman@pasteur.fr
Abbreviations used: AcNPV, 
Autographa californica nuclear 
polyhedrosis virus; cDC, 
  conventional DC; Flt3L, Flt3 
ligand; GalN, d-galactosamine; 
IFNAR−/−, type I IFN receptor 
defi  cient; IRF, IFN regulatory 
factor; μMT, B cell defi  cient; 
MyD88, myeloid diff  erentiation 
factor 88; pDC, plasmacytoid 
DC; TLR, Toll-like receptor; 
TLR-L, TLR ligand.
The online version of this article contains supplemental material.1108  INTERFERON α/β NEGATIVELY CONTROL NEONATAL INFLAMMATION | Zhang et al.
weaker than adult peripheral blood responses (6–8). Human 
DCs derived from cord blood or neonatal monocytes have 
been shown to have a defective IL-12 response to microbial 
stimulation in some studies (9, 10), whereas others reported 
no diff  erence between these and adult cells (8, 11). In mice, 
we and others have shown that purifi  ed neonatal DCs are 
fully competent for IL-12 and IFN-α production in response 
to TLR-L, demonstrating the maturity of the DC compart-
ment for innate responses (12, 13). We have shown that 
  innate activation of IL-10–producing neonatal CD5+ B cells 
infl  uences DC functions for T cell activation in vivo, high-
lighting the critical infl  uence of the neonatal environment (14). 
The TNF-α response of cord blood monocytes to TLR-L 
has been shown to be impaired by plasma factors from cord 
blood (15). These fi  ndings indicate that both humans and mice 
have regulatory mechanisms controlling innate responses that 
are specifi  c to the neonatal period. A more detailed under-
standing of these mechanisms is essential for the improve-
ment of vaccines and the treatment of infectious diseases 
early in life.
Mouse B cells can be divided into B1 cells (including 
CD5+ and CD5− B cells), conventional B2 cells, and mar-
ginal zone B cells based on their diff  erent tissue distribution, 
function, and phenotype. CD5+ B cell development has been 
found to occur primarily in the fetal and perinatal periods, 
and this subset has self-renewal capacity (16). In contrast, the 
Figure 1.  Neonatal CD5+ B cells inhibit the innate pDC response 
to CpG. (A) 4 × 104 neonatal splenic pDCs were cultured alone or in the 
presence of CD5+ or CD5−CD19+ B cells from B6 neonates, or with 
CD19+ B cells from IL-10−/− neonates, and stimulated with 1 μg/ml CpG 
for 48 h. The ratio of CD5+ or CD5− B cells to pDCs was 3:1, and the ratio 
of IL-10−/− B cells to pDCs was 10:1. TNF-α, IL-10, IL-6, and IL-12p70 
were detected in supernatants with Luminex, and IL-12p40 was detected 
by ELISA. *, P < 0.05 versus pDCs alone, pDCs plus CD5− B cells, or pDCs 
plus IL-10−/− B cells. (B) 2 × 104 neonatal splenic pDCs were cultured 
alone or with 2 × 105 splenic B cells from WT, IL-10−/−, or IFNAR−/− 
  neonatal mice or from WT adult mice in the presence of 1 μg/ml CpG for 
48 h. The supernatants were tested for IFN-α and IFN-β content by ELISA. 
pDCs, B cells, or pDCs with B cells cultured in medium alone produced no 
detectable IFN-α/β (not depicted). Data are presented as mean values ± 
SD. ND, not detectable.JEM VOL. 204, May 14, 2007  1109
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B2 cell compartment is poorly developed at the neonatal 
stage, and marginal zone B cells are only found by 3 wk of 
life. The existence of a progenitor specifi  c for B1 cells has 
been a long-running debate. Recently, a pregenitor with the 
Lin−B220lo–negCD19+ phenotype has been identifi  ed  that 
specifi  cally develops into B1 cells (17). The total number and 
activity of this pregenitor peak at the fetal and perinatal stages 
and gradually decrease with age. Several cytokines, including 
IL-7, thymic stromal lymphopoietin, and Flt-3 ligand are 
  involved in the generation and expansion of CD5+ B cells 
(18, 19). CD5+ B cells are an important source of natural 
IgM, which act as the fi  rst line of defense to prevent bacterial 
and viral infections in several mouse models (20–22). How-
ever, one striking feature of these CD5+ B cells is their ability 
to produce IL-10 after TLR triggering (14, 23).
In this paper, we show that neonatal CD5+ B cells play an 
active role in the in vivo control of neonatal infl  ammation. This 
protection of neonates against acute infl  ammation is medi-
ated by the production of IL-10 in response to a large array 
of TLR-Ls and viruses. IFN-α/β were found to be critical 
for this function, as they cooperated with regulatory neonatal 
CD5+ B cells to dampen the infl  ammatory response induced 
by TLR-L, thereby potentially contributing to neonatal sus-
ceptibility to infection.
RESULTS
Neonatal B cells inhibit proinfl  ammatory cytokine 
production by neonatal pDCs after CpG stimulation
We initially investigated the potential role of neonatal B cells 
in regulating pDC function. Neonatal splenic CD5+ and 
CD5− B cells were co-cultured with neonatal splenic pDCs 
(B220+CD11c+mPDCA-1+NK1.1−) in the presence of 
CpG. Under these conditions, neonatal pDCs produced 
smaller amounts of proinflammatory cytokines (TNF-α, 
IL-12p70/p40, and IL-6) in the presence of CD5+ but not 
CD5− B cells in an IL-10–dependent manner (Fig. 1 A). The 
IFN-α/β response of neonatal pDCs to CpG was also strongly 
decreased in the presence of WT neonatal B cells, but not in 
the presence of IL-10−/− neonatal B cells or WT adult B cells 
(Fig. 1 B). Thus, in response to TLR9 signaling, neonatal 
CD5+ B cells inhibit neonatal pDC function in an IL-10–
  dependent manner. These results are consistent with the abil-
ity of IL-10 to impair pDC responses (24). Similar results were 
obtained with neonatal splenic cDCs (Fig. S1, available at 
http://www.jem.org/cgi/content/full/jem.20062013/DC1) 
and macrophages (not depicted).
Neonatal CD5+ B cells produced much larger amounts of 
IL-10 than CD5− B cells after CpG stimulation (Fig. 1 A), 
and signifi  cantly larger amounts of IL-10 were produced in 
the presence of pDCs (Fig. 1 A). The capacity of neonatal 
pDCs to support IL-10 secretion by neonatal B cells after 
CpG stimulation was cell dose dependent (Fig. 2 A). Thus, 
neonatal B cells receive signals from neonatal pDCs that 
  enhance their regulatory role.
Type I IFNs enhance IL-10 production by neonatal B cells 
in response to TLR-L or viral stimulation
We next explored the way in which pDCs increase the 
IL-10–producing capacity of neonatal B cells in response to 
CpG. We investigated whether cytokines secreted by pDCs 
could contribute to IL-10 secretion by neonatal B cells. IFN-
α/β increased IL-10 production by neonatal B cells after 
CpG stimulation, whereas IL-1β, IL-6, IL-12, and TNF-α 
did not (Fig. 2 B). When type I IFN receptor–defi  cient 
(IFNAR−/−) neonatal B cells were co-cultured with neonatal 
pDCs and stimulated with CpG, no increase of IL-10 secretion 
Figure 2.  Type I IFNs enhance IL-10 production by neonatal B cells 
after stimulation with TLR-Ls or viruses. (A–F) Neonatal B cell re-
sponses to various stimuli were analyzed in vitro, under various condi-
tions, in the presence or absence of splenic pDCs (A) or Flt3L-pDCs (C, D, 
and E), as indicated. IL-10 production was assessed by ELISA in superna-
tants at 48 h. B cells and pDCs from B6 neonates were used in all experi-
ments except for (C) and (E), in which cells from 129sv neonates were 
used. Cell cultures were stimulated with 1 μg/ml CpG (A–C), 1,000 HAU/ml 
of infl  uenza virus PR8 (D and F), or 107 PFU/ml AcNPV (D–F). In some ex-
periments, exogenous cytokines were added as indicated (B and F), and 
under these conditions, no IL-10 was detected when B cells were cultured 
with cytokines alone. Data are presented as mean values ± SD.1110  INTERFERON α/β NEGATIVELY CONTROL NEONATAL INFLAMMATION | Zhang et al.
was induced (Fig. 2 C), and IFNAR−/− B cells failed to in-
hibit IFN-α/β production by activated pDCs (Fig. 1 B).
We then analyzed the cross talk between pDCs and 
B cells stimulated with viruses. Baculovirus (Autographa 
californica nuclear polyhedrosis virus [AcNPV]), a DNA virus 
that activates innate cells through TLR9 (25), stimulated 
neonatal B cells to produce minute amounts of IL-10 (Fig. 
2 D). However, the IL-10 response to AcNPV was much 
stronger in the presence of Flt3 ligand (Flt3L)–pDCs and 
depended on type I IFN receptor expression on B cells 
(Fig. 2 E). A sharp increase in IL-10 secretion was also ob-
served if recombinant IFN-α was added to neonatal B cells 
stimulated with AcNPV (Fig. 2 F). Similar results were obtained 
with the heat-inactivated infl  uenza virus PR8 (Fig. 2, D 
and F), an RNA virus targeting TLR7 (26), confi  rming that 
the regulatory activity of neonatal B cells can be triggered 
by viruses.
Neonatal mice have a higher percentage of splenic CD5+ 
B cells than adult mice (27), but neonatal B cells could be 
further divided into three subsets: CD5+CD23−[CD19high
CD43+B220lowAA4.1−IgMhigh], CD5−/dimCD23+[CD19+
CD43−B220high AA4.1−IgM+], and CD5−CD23−[CD19  +
CD43+/−B220+AA4.1+ IgM+/−] (Fig. 3 A and not depicted). 
CD23 expression was lost upon in vitro culture of neonatal 
B cells restricting subset analysis with total B cells, and 
upon CpG stimulation, CD138 expression was increased on 
Figure 3.  Analysis of IL-10 production by neonatal B cell subsets 
in response to various TLR agonists. (A) Phenotypic analysis of freshly 
isolated neonatal CD19+ B cells versus B cells cultured with or without 
CpG. (B) Neonatal splenic CD19+ B cells were sorted as CD5+CD23−, 
CD5−/dimCD23+, and CD5−CD23− subsets and stimulated with 1 μg/ml 
Pam3CSK4, 25 μg/ml Poly(I:C), 10 μg/ml LPS, 1 μg/ml R848, and 1 μg/ml 
CpG with or without 1 ng/ml IFN-β. Data are presented as mean values ± SD. 
(C and D) B6 neonates were injected i.p. with 100 μg CpG, and 3–6 h later, 
splenic B cells were either (C) sorted as CD19+CD5+ and CD19+CD5− 
cells and cultured for 48 h or (D) stained intracellularly with anti–IL-10. 
(D) Continuous lines and shaded histograms show anti–IL-10 and control 
isotype antibodies, respectively, for B cell subsets and T cells (inset shows 
staining of PBS-injected neonates). The numbers in the gates in A, B, and D 
represent cell percentages.JEM VOL. 204, May 14, 2007  1111
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CD5+ B cells showing ongoing plasma cell diff  erentiation 
(Fig. 3 A). Therefore, we sorted these three B cell subsets and 
examined the IL-10 production after stimulation with vari-
ous TLR ligands (TLR2, Pam3CSK4; TLR3, Poly(I:C); 
TLR4, LPS; TLR7, R848; and TLR9, CpG). CD5+CD23− B 
cells produced IL-10 in response to all TLR ligands tested, 
and IL-10 production was increased by type I IFNs (Fig. 3 B). 
CD5−/dimCD23+ B cells produced much less IL-10, and 
CD5−CD23− B cells did not produce any (Fig. 3 B). Simi-
larly, after TLR7 and TLR9 ligand liter stimulation, the very 
few adult splenic CD5+CD23− B cells also produced IL-10, 
whereas the main CD5−CD23+ B cell population produced 
IL-6 (Fig. S2, available at http://www.jem.org/cgi/content/
full/jem.20062013/DC1). Therefore, the propensity of neo-
natal B cells to produce IL-10 refl  ects the hematopoietic 
  developmental program that strongly favors the production of 
CD5+ B cells at the neonatal stage. After the activation of 
neonatal splenic B cells in vivo by CpG, only CD5+ B cells 
secreted a large amount of IL-10 (Fig. 3, C and D). We con-
clude that after stimulation with TLR-Ls or viruses, neonatal 
B cells produce IL-10 and that the level of IL-10 production 
is increased by type I IFNs.
Neonatal B cells inhibit proinfl  ammatory cytokine 
production by pDCs and cDCs in response to various TLR-Ls
We next analyzed the regulatory potential of neonatal B cells 
on the infl  ammatory responses of pDCs and cDCs stimulated 
with various TLR-Ls. Consistent with the known expression 
of TLR7 and TLR9 in pDCs, only pDCs stimulated with 
R848 and CpG produced IFN-α, TNF-α, and IL-12p70. As 
seen with neonatal splenic pDCs, Flt3L-pDCs increased 
IL-10 production by neonatal B cells, whereas IFN-α, TNF-α, 
and IL-12p70 responses were weaker than those of pDCs 
alone (Fig. 4 A). As in pDCs, the production of IFN-β, 
TNF-α, and IL-12p70 by GMCSF-cDCs in response to sev-
eral TLR-Ls (Pam3CSK4, Poly(I:C), LPS, R848, and CpG) 
was inhibited by WT neonatal B cells but not by IL-10−/− 
neonatal B cells (Fig. 4 B). Identical results were obtained 
with cDCs purifi  ed from neonatal spleen (Fig. S1 and unpub-
lished data). cDCs also greatly increased the capacity of neo-
natal B cells to produce IL-10 (Fig. 4 B), with this increase 
being type I IFN dependent (not depicted).
Collectively, these data show that neonatal CD5+ B cells 
are intrinsically prone to produce IL-10 after TLR-L and virus 
stimulation, enabling them to down-regulate the infl  ammatory 
Figure 4.  Neonatal B cells inhibit the production of proinfl  amma-
tory cytokines in response to various TLR-Ls. (A and B) 5 × 105 B cells 
from B6 or IL-10−/− neonatal mice were cultured with 5 × 104 Flt3L-
pDCs (A) or GMCSF-cDCs in the presence of 1 μg/ml Pam3CSK4, 25 μg/ml 
Poly(I:C), 10 μg/ml LPS, 1 μg/ml R848, and 1 μg/ml CpG for 48 h. 
(A) IFN-α, (B) IFN-β, and (A and B) TNF-α, IL-12p70, and IL-10 were detected 
in supernatants by ELISA. NA, not applicable. No detectable infl  ammatory 
cytokine was produced by pDCs in response to Pam3CSK4, Poly(I:C), and 
LPS. Data are presented as mean values ± SD. (C) B6 neonates and adults 
were injected with GalN, together with TLR-L, and survival was monitored 
for 3 d. The following doses were used: 4 mg/kg Pam3CSK4, 2 mg/kg 
Poly(I:C), 4 mg/kg LPS, 2 mg/kg R848, and 4 mg/kg CpG. 0.35 g/kg GalN 
was used for Poly(I:C)-, LPS-, and CpG-injected groups, and 1 g/kg GalN 
was used for Pam3CSK4- and R848-injected groups.1112  INTERFERON α/β NEGATIVELY CONTROL NEONATAL INFLAMMATION | Zhang et al.
responses of pDCs and cDCs. In addition, type I IFNs cooper-
ate with B cells to increase IL-10 production, thereby restrict-
ing neonatal infl  ammatory responses to TLR triggering.
Impaired infl  ammation in neonatal mice 
after TLR triggering
We next monitored the infl  ammatory responses induced 
in vivo by several TLR-Ls in neonates and adults, using 
d-  galactosamine (GalN)–sensitized mice lethally susceptible to 
infl  ammation (28). Although adult mice succumbed to a lethal 
shock induced by all TLR-Ls tested, very few neonatal mice, 
if any, died, even after challenge with a high dose of CpG 
(Fig. 4 C and Fig. 5 A). We measured neonatal infl  ammatory 
responses by analyzing TNF-α, IL-1β, IL-6, and IL-12p70 
responses in the spleen after CpG challenge. Under these 
conditions, CpG induced infl  ammatory cytokine production 
in the adult spleen, whereas no response was observed in 
  neonates. Likewise, high levels of IL-12p40 were induced 
in the adult liver, spleen, and lungs, whereas IL-12p40 was 
barely detectable in neonatal organs (Fig. 5 C). We then in-
vestigated the potential role of IL-10 in curtailing neonatal 
infl  ammation in vivo. IL-10−/− neonates, like WT adults, 
died when challenged with a low dose of CpG (Fig. 5 A). 
Large amounts of IL-12p40 were induced in the IL-10−/− 
neonatal liver, spleen, and lungs, demonstrating the critical 
role of IL-10 in controlling neonatal infl  ammation (Fig. 5 C). 
Thus, WT neonates failed to develop an effi   cient infl  amma-
tory response, but adult-like infl  ammation can be induced in 
the absence of IL-10.
CD5+ B cell–derived IL-10 can control lethal infl  ammation
We next investigated the role of B cell–derived IL-10 in 
  controlling neonatal infl  ammation after TLR9 ligation. We 
treated B cell–defi  cient (μMT) neonates, which lack the ma-
ture B cell compartment, with GalN and CpG. Unlike WT 
neonates, μMT neonates succumbed to CpG challenge, 
demonstrating the induction of an infl  ammatory response 
(Fig. 6 A). Accordingly, the IL-12p40 response in the liver 
and spleen was stronger in μMT than in WT neonates after 
CpG injection (Fig. 6 B). Similarly, spleen cells from μMT 
neonates injected with CpG produced larger amounts of 
TNF-α and IL-12p70, but lower amounts of IL-10, than 
WT spleen cells did (Fig. 6 C). RAG2−/− neonates, as well 
as Vav1−/− neonates, which lack the CD5+ B cell compart-
ment (Fig. 6 D), were as susceptible to CpG challenge as μMT 
neonates (Fig. 6 A). In contrast to WT CBA/J neonates, CBA/
Xid neonates, which also lack IgM+CD5+ B cells, pro-
duced much less IL-10 and larger amounts of IL-12p70 and 
were susceptible to GalN/CpG challenge (Fig. S3, available 
at http://www.jem.org/cgi/content/full/jem.20062013/DC1). 
Figure 5.  Impaired neonatal infl  ammation in response to CpG 
is IL-10–dependent. (A) WT neonates (day 1 and 7), IL-10−/− neonates 
(day 7), and WT adults were injected i.p. with 0.35 g/kg GalN and the indi-
cated dose of CpG, and survival was monitored for 3 d. *, P < 0.05 versus 
WT adults or IL-10−/− day 7 neonates. (B and C) WT or IL-10−/− neonates 
or WT adults were injected with 4 mg/kg CpG or ODN1982, and TNF-α, 
IL-1β, IL-6, IL-12p70, and IL-12p40 were detected by ELISA in the spleen 
(B and C), liver (C), and lungs (C), harvested at 1.5, 3, or 6 h. Four to nine 
mice were used for each time point. Data are presented as mean values ± 
SD. ND, not detectable.JEM VOL. 204, May 14, 2007  1113
ARTICLE
Flt3L administration to neonatal mice selectively increased 
the numbers of pDCs and cDCs (29) but not of CD5+ B cells 
(Fig. S4). Flt3L-treated neonates were shown to be more re-
sistant to Listeria infection (29), and we found that these neo-
nates were susceptible to CpG challenge (Fig. S4), indicating 
that changes in the balance between CD5+ B cells and DCs 
increased neonatal infl  ammation. We next assessed the capac-
ity of B cell–derived IL-10 to control neonatal infl  ammation. 
Transfer of WT, but not IL-10−/−, neonatal B cells provided 
protection to μMT neonates against GalN/CpG-induced 
death (Fig. 6 E). Identical results were obtained in IL-10−/− 
neonates, which develop lethal infl  ammation to CpG in the 
absence of GalN (Fig. 6 F). Among WT B cells, only 
CD5+CD23− B cells, but not CD5−/dimCD23+ B cells, were 
able to rescue IL-10−/− neonates. Collectively, these results 
show that CD5+ B cell–derived IL-10 is involved in the con-
trol of neonatal infl  ammation.
Type I IFNs display pro- and antiinfl  ammatory properties 
in adults and neonates, respectively
We next investigated the role of type I IFN in the regula-
tion of infl  ammation. We detected IFN-α/β in sera from 
both WT and IFNAR−/− mice after the administration of 
20 mg/kg CpG (Fig. S5, available at http://www.jem.org/cgi/ 
content/full/jem.20062013/DC1). In adult sera, IL-12p70 and 
TNF-α were signifi  cantly lower in IFNAR−/− than in WT 
mice, and IL-10 was barely detectable in either strain. In con-
trast, no signifi  cant diff  erence in serum TNF-α and IL-12p70 
responses was observed between WT and IFNAR−/− neonates. 
The serum IL-10 response was much weaker in IFNAR−/− 
Figure 6.  Neonatal infl  ammation is restored in the absence of 
CD5+ B cells. (A) Neonatal and adult mice of the indicated strains were 
injected with 1 g/kg GalN and 4 mg/kg CpG, and survival was monitored 
for 3 d. Data are cumulative results for two to four experiments. (B) 3 h 
after a 4-mg/kg CpG injection, the IL-12p40 response was analyzed in the 
liver and spleen of B6 or μMT neonates and adult mice. Data from indi-
vidual neonatal mice, obtained in three independent experiments, are 
expressed as the neonate/adult IL-12 response ratio (induced in the same 
experiment). Horizontal lines represent means. (C) B6 and μMT neonates 
were injected with CpG, and 3 h later, splenocytes were recovered and 
cultured for 24 h. TNF-α, IL-12p70, and IL-10 were detected in superna-
tants by ELISA. ND, not detectable. Data are presented as mean values ± 
SD. (D) CD5 expression by neonatal spleen B cells in WT and vav1−/− neo-
nates. The numbers in the gates represent cell percentages. (E and F) μMT 
or IL-10−/− neonates received 8 × 106 CD19+ B cells from WT or IL-10−/− 
neonatal mice or were left untreated. μMT neonates were challenged 
with 1 g/kg GalN, plus 10 μg CpG and IL-10−/− with 30 μg CpG alone. 
(F) IL-10−/− neonates alternatively received 1.8–2 × 106 CD5−/dimCD23+ 
or 1.2–1.5 × 106 CD5+CD23− WT neonatal B cells before CpG challenge. 
Survival was monitored for 3 d.1114  INTERFERON α/β NEGATIVELY CONTROL NEONATAL INFLAMMATION | Zhang et al.
than in WT neonates (Fig. S5). We examined IL-12p40 re-
sponses in the liver, spleen, and lungs, after the injection of 
a low dose (4 mg/kg) of CpG, in both neonates and adults 
(IL-12p70, TNF-α, and IL-10 were not detectable under 
these conditions). The lack of an IFN-α/β receptor in adult 
mice resulted in a signifi  cantly weaker IL-12p40 response in 
the spleen and liver, with the opposite observed in neonates 
(Fig. 7 A). Consistently, IFNAR−/− neonates sensitized with 
GalN were more susceptible to CpG challenge than WT ne-
onates, whereas IFNAR−/− adults were more resistant than 
their WT counterparts (Fig. 7 B). Thus, type I IFNs are pro-
infl  ammatory in adults but decrease infl  ammation in neo-
nates upon TLR9 signaling, with this eff  ect being correlated 
with the eff  ects on IL-10 production. Interestingly, pDCs 
and cDCs displayed similar levels of activation in IFNAR−/− 
and WT neonates after CpG injection (Fig. 7 C). CD5+ B 
cells were also similarly activated under these conditions (Fig. 
7 C), and B cells from IFNAR−/− neonates produced much 
less IL-10 than WT B cells (Fig. 7 D), consistent with the 
lower serum IL-10 concentration in IFNAR−/− neonates 
(Fig. S5). Similar results were obtained after Pam3CSK4 in-
jection (Fig. 7 D and not depicted), confi  rming that IFN-α/β 
are important for IL-10 production by neonatal B cells 
in vivo. Spleen cells from IFNAR−/− neonates injected with 
CpG produced more TNF-α than did WT spleen cells (Fig. 
7 E). In contrast, IFNAR−/− adults displayed a weaker re-
sponse than WT adults.
WT, but not IFNAR−/−, neonatal B cells can rescue neonates 
from lethal infl  ammation
We therefore directly assessed the infl  uence of IFN-α/β in 
the ability of B cell–derived IL-10 to control lethal infl  am-
mation to CpG in IL-10−/− neonates in the absence of GalN 
(Fig. 7 F). After the adoptive transfer of neonatal, but not 
adult, WT B cells, IL-10−/− neonates survived CpG chal-
lenge (Fig. 7 F). This protection was TLR9 dependent, as 
TLR9−/− neonatal B cells failed to rescue IL-10−/− neonates. 
IFNAR−/− neonatal B cells also failed to confer protection to 
IL-10−/− recipients after CpG challenge (Fig. 7 F). Intact 
type I IFN signaling in neonatal B cells is therefore required 
to complement the IL-10 defi  ciency of the recipient neo-
nates in the context of CpG-induced infl  ammation. Thus, 
the negative regulatory role of type I IFNs in neonatal in-
fl  ammation is linked to the positive eff  ect of these molecules 
on IL-10 production by innately activated neonatal B cells.
D  I  S  C  U  S  S  I  O  N 
In this paper, we show that both type I IFNs and B cells 
play a major role in restricting infl  ammation early in life. 
We found that neonatal B cells negatively regulated type I 
IFNs and the infl  ammatory responses of pDCs and cDCs by 
producing IL-10 in response to a large array of TLR-Ls 
and viruses. Maximal IL-10 production by neonatal B cells 
in vivo and the subsequent control of acute infl  ammation 
require a functional type I IFN system (Fig. S6, available at 
http://www.jem.org/cgi/content/full/jem.20062013/DC1). 
This regulatory mechanism can also protect against lethal 
infl  ammation.
The early postnatal period is characterized by a high level 
of susceptibility to various infections, to which the mecha-
nism described in this paper may contribute. The balance be-
tween pro- and antiinfl  ammatory cytokines is a critical factor 
in the control of infections. Neonatal Listeria infection is 
  associated with a strong IL-10 production, and anti–IL-10 
treatment protects neonatal, but not adult, mice against infec-
tion (30). CpG increases neonatal resistance to listeriosis in 
correlation with IL-12 production in vivo (31), but less effi   -
ciently in neonates than in adults. In this paper, we show a 
defi  cit in the infl  ammatory response elicited by CpG in neo-
natal mice. We were able to restore an adult-like infl  amma-
tory response to CpG in IL10−/− neonates, but these animals 
died within 24 h. IL-12 administration enhances the immune 
responses of neonatal mice to vaccines (32, 33) but may lead 
to growth retardation and death (34). Neonates are highly 
likely to encounter infl  ammatory stimuli because of their abrupt, 
massive exposure to microbes. Therefore, this transition pe-
riod requires tight control over potentially immunopatho-
physiological mediators for optimal neonatal develo  pment. 
Accordingly, our study establishes that neonates develop 
much weaker systemic infl  ammatory responses than adults in 
response to various TLR-Ls because of an active regulatory 
mechanism mediated by the innate response of neonatal B cells 
to these stimuli.
TLR signaling is a critical component in the initiation of 
T cell immune responses through DC activation. Consistent 
with the large array of TLRs expressed by B cells (35), the 
generation of T cell–dependent antibodies also requires B 
cell activation via TLRs (36). We report that innate activa-
tion of neonatal CD5+ B cells by TLR-Ls and viruses may 
provide an inhibitory environment through the secretion of 
IL-10. CD5+ B cells are thought to originate in the fetal liver 
and to undergo self-renewal in the periphery (37). Neonatal 
livers display high levels of hematopoietic activity, probably 
contributing to the abundance of CD5+ B cells in the spleen, 
liver, and peripheral blood of neonatal mice (unpublished 
data) (14), a characteristic shared by human cord blood (38). 
The CD5+ B cells in adult mice are the B1a cells located pri-
marily in the peritoneum and known to produce IL-10 (23). 
We show that CD5 expression does not defi  ne a single ho-
mogeneous B cell population in the neonatal spleen. A sub-
stantial number of conventional CD23+ B2 cells are CD5dim, 
whereas adult CD23+ B2 cells are negative for CD5. After 
TLR signaling, neonatal CD5−/dimCD23+ B cells innately 
produce IL-10, but much less than CD5+CD23− B cells. 
Conversely, adult CD23+ B2 cells produce large amounts of 
IL-6, but no IL-10, in response to TLR stimulation. The 
diff  erences in cytokine production by neonatal and adult 
B cells after TLR triggering clearly require further investiga-
tion. However, the tendency for neonatal B cells to produce 
IL-10 and the high frequency of CD5+ B cells suggest that 
the systemic antiinfl  ammatory role of these cells is develop-
mentally controlled.JEM VOL. 204, May 14, 2007  1115
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Type I IFNs play a key role in host defense, either directly 
or by modulating innate and adaptive immune responses. 
Type I IFNs may directly act on CD8+ T cells, B cells, NK 
cells, and DCs, enhancing their functions (39). The enhance-
ment of neonatal B cell IL-10 production by type I IFNs 
raises questions about the role of type I IFNs in infl  ammation. 
Both proinfl  ammatory cytokines and type I IFNs are produced 
after TLR triggering. Proinfl  ammatory cytokines are mostly 
induced by activation of the NF-κB pathway and the mitogen-
activated protein kinase pathway, whereas a diff  erent panel of 
downstream molecules are preferentially used for type I IFN pro-
duction (40). IFN regulatory factor (IRF) 7 directly associates 
Figure 7.  Type I IFN signaling restricts the neonatal infl  ammation 
induced by CpG through IL-10–secreting B cells. (A) IL-12p40 was 
detected in the liver, spleen, and lungs of neonatal (n = 3) and adult (n = 4) 
129sv or IFNAR−/− mice harvested 3 h after a 4-mg/kg CpG i.p. injec-
tion. The data shown are representative of three independent experi-
ments. (B) WT and IFNAR−/− neonates and adults were injected i.p. with 
1 g/kg GalN and 4 mg/kg CpG, and survival was monitored for 3 d. The cu-
mulative results obtained in three to fi  ve experiments are shown. (C) WT 
and IFNAR−/− neonates were injected i.p. with 20 mg/kg CpG or left un-
treated. 3 h later, splenic CD5+ B cells, pDCs, and cDCs were analyzed for 
up-regulation of the CD69 and I-Ab activation markers. Nontreated: WT 
(thin line) and IFNAR−/− (dotted line); CpG: WT (shaded area) and 
IFNAR−/− (bolded line). (D) WT and IFNAR−/− neonates were injected i.p. 
with 20 mg/kg CpG, 4 mg/kg Pam3CSK4, or PBS, and CD19+ cells were 
purifi  ed 3 h later. IL-10 was detected in cell culture supernatants by ELISA. 
(E) WT and IFNAR−/− neonatal or adult mice were injected i.p. with 
20 mg/kg CpG, and 3 h later, spleen cells were recovered and cultured for 
24 h. TNF-α was detected in supernatants by ELISA. (F) IL-10−/− neonates 
received 8 × 106 neonatal B cells from WT, TLR9−/−, or IFNAR−/− mice 
or adult WT B cells, or were left untreated. They were then challenged 
with 30 μg CpG. Survival was monitored for 7 d. ND, not detectable. 
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with MyD88 to initiate IFN-α/β transcription, whereas both 
IRF3 and IRF7 are important in the MyD88-independent 
pathway. IRF3 directs primary IFN-β induction, stimulating 
IRF7 production and forming a positive loop for IFN-α/β 
production (5). The biological eff  ects of type I IFNs are prin-
cipally through the IFNAR/STAT1-dependent pathway (39), 
but this signaling may be inhibited by IL-10 (41).
Our in vivo results show that type I IFNs have proinfl  am-
matory and antiinfl  ammatory eff  ects in adult mice and neo-
nates, respectively, after CpG injection. Type I IFNs decrease 
infl  ammation by indirectly increasing the capacity of neonatal 
B cells to produce IL-10, and this regulatory loop is critical 
for control of the lethal infl  ammation induced by CpG. Op-
posite eff  ects of type I IFNs on infl  ammation have been re-
ported. Type I IFNs are indispensable in the mouse model of 
LPS-induced lethal shock (42). The potent proinfl  ammatory 
eff  ects of type I IFNs have been implicated in STAT1-
  dependent increases in the expression of infl  ammation genes 
(43, 44). A type I IFN autocrine–paracrine loop is required 
for maximal IL-12p70 and TNF-α secretion by GMCSF-
generated DCs after TLR-L stimulation (44, 45). Antiinfl  am-
matory eff  ects of type I IFNs have also been reported in 
experimental colitis (46), and a possible role for STAT3 
in inhibiting the STAT1 pathway has been proposed (47). 
In vivo, type I IFNs block IL-12 production by splenic DCs 
during mouse CMV infection (48), and the selective deple-
tion of pDCs in vivo markedly decreases IFN-α and in-
creases IL-12p70 responses in the sera of mouse CMV–infected 
mice (49). Collectively, these results suggest that type I IFNs 
indirectly inhibit IL-12 production. The capacity of DCs to 
drive neonatal T cell responses was impaired for Th1, but not 
CTL, responses (14). Given the positive role of IL-10 in CTL 
responses (50) and the negative role of IL-10 in inhibiting 
type I IFNs, the production of other cytokines, and CpG-
activated pDC survival (24), further work is required to de-
termine the exact relationship between neonatal B cells and 
pDCs during viral infection in vivo.
In summary, we describe in this paper a new role for type 
I IFNs in the control of infl  ammation mediated by non-
specifi  c activation of B cells. A previous study has shown that 
autoantigen-dependent secretion of IL-10 by B cells is im-
portant for inhibiting T cell–mediated pathogenesis (51). The 
regulatory role of innate B cells in controlling acute systemic 
infl  ammation in neonatal mice is demonstrated in this paper. 
This regulatory mechanism helps in providing an innocuous 
environment for the growth and development of neonates 
and may explain their high susceptibility to infections.
MATERIALS AND METHODS
Mice. C57BL/6 (B6) mice were purchased from Janvier, and 129sv mice were 
purchased from Charles River Laboratories. CBA/J and CBA/Xid mice were 
purchased from Harlan. IL-10−/−, μMT (both obtained from A. Bandeira, In-
stitut Pasteur, Paris, France), TLR9−/− (obtained from P. Viera, Institut Pas-
teur, Paris, France), vav1−/− (52), and RAG2−/− mice were all of the C57BL/6 
background. IFNAR−/− mice were also of either the 129sv or C57BL/6 back-
grounds. Pups were obtained from females mated and housed on site in specifi  c 
pathogen-free conditions. Neonatal mice were 7 d old, unless specifi  cally stated 
otherwise, and adult mice were 6–10 wk old. Similar B cell subsets were found 
in IL-10−/−, IFNAR−/−, TLR9−/−, and WT neonates. Animal studies were 
approved by the Institut Pasteur Safety Committee in accordance with French 
and European guidelines.
Culture medium and reagents. Complete medium consisted of RPMI 1640 
containing l-alanyl-l-glutamine supplemented with 5–10% FCS (MP Bio-
medicals), 5 × 10−5 M 2-Mercaptoethanol (Sigma-Aldrich), and antibiotics 
(100 U/ml penicillin and 100 μg/ml streptomycin; Invitrogen). In some ex-
periments, cells were cultured in HL-1 serum-free medium (Bio Whittaker). 
TLR9 ligand type B CpG (CpG 1826, 5′-T  C  C  A  T  G  A  C  G  T  T  C  C  T  G  A  C-
G  T  T  -3′) and control (ODN 1982, 5′-T  C  C  A  G  G  A  C  T  T  C  TCTCAGGTT-3′) 
were synthesized by Proligo with phosphorothioated backbones. TLR2 
  ligand Pam3CSK4, TLR3 ligand Poly(I:C), TLR4 ligand LPS (from Esche-
richia coli 0111:B4), and TLR7 ligand R848 were purchased from Invivogen. 
Human infl  uenza virus A/PR/8/34 (PR8 [H1N1]; Charles River Laborato-
ries) was inactivated by heating at 56°C for 30 min before use. Baculovirus 
(AcNPV) was purchased from Agate. The antibodies used were anti-CD11c 
(HL3), anti-B220 (RA3-6B2), anti-CD19 (1D3), anti-IgM (II/41), anti-
NK1.1 (PK136), anti-CD5 (53–7.3), anti–mPDCA-1, and anti-IL10 ( JES5-
16E3). All mAbs were obtained from BD Biosciences, except anti–mPDCA-1 
(Miltenyi Biotec).
Cell purifi  cation and FACS analysis. Spleens from neonatal mice were 
treated with collagenase D and DNase I (Roche Molecular Biochemicals) 
for 30 min and dissociated in Ca2+-free medium in the presence of EDTA. 
The preparation was enriched in DCs, using anti-CD11c (N418; Miltenyi 
Biotec) and anti–mPDCA-1 MicroBeads (Miltenyi Biotec), in an automated 
magnetic cell sorter (AutoMACS; Miltenyi Biotec). Neonatal cDCs and 
pDCs were further purifi  ed by fl  ow cytometry to obtain cDCs (CD11chigh) 
and pDCs (CD11clow, B220+, NK1.1−, CD19−), using a FACSAria (BD 
Biosciences) or a MoFlo (DakoCytomation) apparatus. B cells were purifi  ed 
using anti-CD19 MicroBeads (Miltenyi Biotec) on an AutoMACS cell 
sorter. In some experiments, neonatal CD19+ cells were further sorted by 
fl  ow cytometry to obtain CD5+CD23−, CD5−/dimCD23+, and CD5−CD23− 
B cell subsets. Each sorted cell population was 97–99% pure. Flt3L-pDCs 
and GMCSF-cDCs were obtained, as previously described, from bone mar-
row cells cultured with Flt3L (53) and GMCSF (54), respectively. Flt3L-
pDCs and GMCSF-cDCs were purifi  ed using anti-B220 and anti-CD11c 
MicroBeads (Miltenyi Biotec), respectively. The preparations were >95% 
pure for Flt3L-pDCs and >99% pure for GMCSF-cDCs.
Cytokine determinations. Neonatal cDCs, pDCs, and B cells were cul-
tured in HL-1 serum-free medium and stimulated with various TLR-Ls or 
viruses for 48 h. In some experiments, recombinant IL-1β, IL-6, IL-12, 
TNF-α, IFN-α, and IFN-β (all obtained from R&D Systems) were added 
to the medium. IL-6, IL-10, IL-12p40, IL-12p70, and TNF-α were deter-
mined by standard sandwich ELISA, with appropriate antibodies (all ob-
tained from BD Biosciences), or with a multiplex kit (Bio-Rad Laboratories) 
and a Luminex X-100 apparatus (Luminex Corporation). Mouse IFN-α/β 
were detected with the corresponding ELISA kits (PBL Biomedical Labora-
tories), used according to the manufacturer’s instructions.
For direct cytokine detection in organs, neonatal and adult mice were 
injected with CpG1826 or ODN1982 (4 mg/kg of body weight). At various 
time points, liver, spleen, and lungs were collected and homogenized in 
RIPA buff  er (Sigma-Aldrich) supplemented with protease inhibitor cocktail 
(Roche Molecular Biochemicals), using Tissue Lyser (QIAGEN). Samples 
were centrifuged at 12,000 g for 15 min at 4°C, and the supernatant was col-
lected and stored at −80°C. IL-12p40 was detected by ELISA. Plates were 
developed with streptavidin-alkaline phosphatase (BD Biosciences) and 
p-nitrophenylphosphate (Sigma-Aldrich).
Galactosamine-sensitized shock experiment. Suckling pups from each 
litter were randomly assigned to experimental groups, marked, and kept 
with the mother until the completion of the experiments. Neonatal and JEM VOL. 204, May 14, 2007  1117
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adult mice were intraperitoneally injected with GalN (0.35 or 1 g/kg of 
body weight; Sigma-Aldrich) and various TLR-Ls. All materials were dis-
solved and diluted in pyrogen-free PBS. Injection volumes were 100 and 
500 μl for neonatal and adult mice, respectively. Deaths were recorded every 
24 h for 3 d.
B cell adoptive transfer experiments. CD19+ B cells or B cell subsets 
were purifi  ed from B6 neonates, B6 adults, IL-10−/− neonates, IFNAR−/− 
neonates (B6 background), and TLR9−/− neonates and transferred into 
day 7 μMT or IL-10−/− neonates (each recipient received 8 × 106 B cells 
or 1–2 × 106 B cell subsets i.p. in 50 μl). Control litters received PBS. 
Neonates were challenged intraperitoneally, as indicated in the fi  gures, with 
CpG1826 in 50 μl PBS. Survival was monitored for 3–7 d.
Statistics. Student’s t tests were used to compare groups (data are presented 
as mean values ± SD). Fisher’s exact test was used to compare survival rates. 
Survival curves were analyzed with log-rank tests. P < 0.05 was considered 
statistically signifi  cant.
Online supplemental material. Fig. S1 shows inhibition of IL-12–cDC 
response by neonatal B cells after CpG stimulation. Fig. S2 shows cytokine 
response of adult splenic B cell subsets to TLR agonists. Fig. S3 shows resto-
ration of infl  ammatory responses in Xid neonates. Fig. S4 shows lethal in-
fl  ammation induced by CpG in Flt3L-treated neonates. Fig. S5 shows seric 
cytokines induced by CpG in IFNAR−/− and WT neonatal mice. Fig. S6 
corresponds to a scheme showing the regulation of the neonatal acute in-
fl  ammatory response by B cells and IFN-α/β. Online supplemental material 
is available at http://www.jem.org/cgi/content/full/jem.20062013/DC1.
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